logo
logo

Aim Immuno Tech announced it raised $3.3 Million in an amended filing from an offering of $3.3 Million

Feb 21, 2024•over 1 year ago

Amount Raised

$3.3 Million

Round Type

seed

OcalaTherapeuticsPharmaceuticalBiotechnologyHealth Care

Company Information

Company

AIM ImmunoTech

Location

Ocala, Florida, United States

About

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

Related People